A perspective on surrogate endpoints in controlled clinical trials (Q5424596): Difference between revisions
From MaRDI portal
Added link to MaRDI item. |
Normalize DOI. |
||
| (3 intermediate revisions by 3 users not shown) | |||
| Property / DOI | |||
| Property / DOI: 10.1191/0962280204sm362ra / rank | |||
| Property / MaRDI profile type | |||
| Property / MaRDI profile type: MaRDI publication profile / rank | |||
Normal rank | |||
| Property / OpenAlex ID | |||
| Property / OpenAlex ID: W2340418739 / rank | |||
Normal rank | |||
| Property / Wikidata QID | |||
| Property / Wikidata QID: Q35805910 / rank | |||
Normal rank | |||
| Property / DOI | |||
| Property / DOI: 10.1191/0962280204SM362RA / rank | |||
Normal rank | |||
Latest revision as of 16:58, 30 December 2024
scientific article; zbMATH DE number 5208640
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A perspective on surrogate endpoints in controlled clinical trials |
scientific article; zbMATH DE number 5208640 |
Statements
A perspective on surrogate endpoints in controlled clinical trials (English)
0 references
5 November 2007
0 references
